


- > In Q2 2016, **£211m** (£196m) was invested in **34** (30) deals of over £0.5m by **61** investors
- > In the year to date, **£561m** (£324m) was invested in **68** (68) deals
- > The busiest investors were Albion Ventures (inc UCL Deals), Enterprise Ireland, London Business Angels, Oxford Sciences Innovation, Scottish Investment Bank and Syndicate Room
- > **85%** (67%) of deals involved more than one investor
- > **71%** of deals were less than **£5m** in value, these received **17%** of money invested
- > Private investors participated in **47%** (27%) of deals and Crowdfunding platforms financed **12%** (7%) of deals
- > Corporate investors participated in **9%** of deals, European investors in **6%** and US Investors in **9%**
- > There have been four primary areas of investment focus – Therapeutics (**£154m**, **10 companies**), Devices/Diagnostics (**£16m**, **11 companies**), Biotech/Clinical Services (**£34m**, **8 companies**) and Health Software/Online Services (**£5.6m**, **4 companies**).



- > The 10 biggest deals (with disclosed values) received **83%** of funds invested, were:

F2G	£42m
Freeline Therapeutics	£26m
Orchard Therapeutics	£21m
OxStem	£17m
Vaccitech	£13m
Medical Imaging Partnership	£12m
Storm Therapeutics	£12m
EvOx Therapeutics	£10m
Mironid	£6m

- > The most active regions were London, Ireland, Scotland and Cambridge which were responsible for **26%**, **18%**, **12%** and **12%** of deals respectively.
- > The North, Thames Valley and London received **22%**, **20%** and **18%** (respectively) of the funds invested in the UK and Ireland. All other regions took less than **10%**.
- > On a City basis: London, Cambridge, Dublin and Oxford had multiple LS transactions and together were responsible for **62%** of deals

